Advances on reprogramming of fatty acid metabolism in pulmonary fibrosis

doi:10.16352/j.issn.1001-6325.2024.04.0548

Abstract

Abstract: Pulmonary fibrosis is a progressive interstitial fibrotic lung disease with high mortality. Its pathogenesis is complex and involves the reprogramming of fatty acid metabolism. This reprogramming includes changes in de novo fatty acid synthesis, uptake, oxidation, and derivatives. It crucially influences alveolar epithelial cell survival, macrophage polarization, and fibroblast activation, thereby playing a significant role in either exacerbating or mitigating the disease. Understanding and intervening in the reprogramming of fatty acid metabolism offers potential strategies for prevention, diagnosing and treatment of pulmonary fibrosis.

Key words: fatty acids, pulmonary fibrosis, metabolic reprogramming

CLC Number:

R563

BAI Lu, WANG Jiaxin, WANG Xue, ZENG Wei, SONG Meiyue, ZHANG Tiantian, WANG Jing. Advances on reprogramming of fatty acid metabolism in pulmonary fibrosis[J]. Basic & Clinical Medicine, 2024, 44(4): 548-552.

References 24

[1]	Kim HS, Yoo HJ, Lee KM, et al. Stearic acid attenuates profibrotic signalling in idiopathic pulmonary fibrosis[J]. Respirology, 2021, 26: 255-263.
[2]	Galdino de Souza D, Santos DS, et al. Fish oil nanoemulsion supplementation attenuates bleomycin-induced pulmonary fibrosis BALB/c mice[J]. Nanomaterials(Basel), 2022, 12: 1683. doi: 10.3390/nano12101683.
[3]	Sunaga H, Matsui H, Ueno M, et al. Deranged fatty acid composition causes pulmonary fibrosis in Elovl6-deficient mice[J]. Nat Commun, 2013, 4: 2563. doi: 10.1038/ncomms3563.
[4]	Romero F, Hong X, Shah D, et al. Lipid synthesis is required to resolve endoplasmic reticulum stress and limit fibrotic responses in the lung.[J]. Am J Respir Cell Mol Biol, 2018, 59: 225-236.
[5]	Shin H, Park S, Hong J, et al. Overexpression of fatty acid synthase attenuates bleomycin induced lung fibrosis by restoring mitochondrial dysfunction in mice[J]. Sci Rep, 2023, 13: 9044. doi: 10.1038/s41598-023-36009-3.
[6]	Jung MY, Kang JH, Hernandez DM, et al. Fatty acid synthase is required for profibrotic TGF-β signaling[J]. Faseb J, 2018, 32: 3803-3815.
[7]	Kwak D, Bradley PB, Subbotina N, et al. CD36/Lyn kinase interactions within macrophages promotes pulmonary fibrosis in response to oxidized phospholipid[J]. Respir Res, 2023, 24: 314. doi: 10.1186/s12931-023-02629-6.
[8]	Pei Z, Fraisl P, Shi X, et al. Very long-chain acyl-CoA synthetase 3: overexpression and growth dependence in lung cancer[J]. PLoS One, 2013, 8: e69392. doi: 10.1371/journal.pone.0069392.
[9]	Yang S, Kobayashi S, Sekino K, et al. Fatty acid-binding protein 5 controls lung tumor metastasis by regulating the maturation of natural killer cells in the lung[J]. FEBS Lett, 2021, 595: 1797-1805.
[10]	Speca S, Dubuquoy C, Rousseaux C, et al. GED-0507 attenuates lung fibrosis by counteracting myofibroblast transdifferentiation in vivo and in vitro[J]. PLoS One, 2021, 16: e0257281. doi: 10.1371/journal.pone.0257281.
[11]	Liu Y, Chen S, Yu L, et al. Pemafibrate attenuates pulmonary fibrosis by inhibiting myofibroblast differentiation[J]. Int Immunopharmacol, 2022, 108: 108728. doi: 10.1016/j.intimp.2022.108728.
[12]	Koudelka A, Cechova V, Rojas M, et al. Fatty acid nitroalkene reversal of established lung fibrosis[J]. Redox Biol, 2022, 50: 102226. doi: 10.1016/j.redox.2021.102226.
[13]	Wei A, Gao Q, Chen F, et al. Inhibition of DNA methylation de-represses peroxisome proliferator-activated receptor-γ and attenuates pulmonary fibrosis[J]. Br J Pharmacol, 2022, 179: 1304-1318.
[14]	Zhang Y, Li T, Pan M, et al. SIRT1 prevents cigarette smoking-induced lung fibroblasts activation by regulating mitochondrial oxidative stress and lipid metabolism[J]. J Transl Med, 2022, 20: 222. doi: 10.1186/s12967-022-03408-5.
[15]	Wu W, Zhang G, Qiu L, et al. Contribution of adiponectin/carnitine palmityl transferase 1A-mediated fatty acid metabolism during the development of idiopathic pulmonary fibrosis[J]. Oxid Med Cell Longev, 2022, 2022: 5265616. doi: 10.1155/2022/5265616.
[16]	Gu L, Surolia R, Larson-Casey JL, et al. Targeting Cpt1a-Bcl-2 interaction modulates apoptosis resistance and fibrotic remodeling[J]. Cell Death Differ, 2022, 29: 118-132.
[17]	Pang J, Qi X, Luo Y, et al. Multi-omics study of silicosis reveals the potential therapeutic targets PGD(2) and TXA(2)[J]. Theranostics, 2021, 11: 2381-2394.
[18]	Suzuki T, Kropski JA, Chen J, et al. Thromboxane-prostanoid receptor signaling drives persistent fibroblast activation in pulmonary fibrosis [J]. Am J Respir Crit Care Med, 2022, 206: 596-607.
[19]	Fortier SM, Penke LR, King D, et al. Myofibroblast dedifferentiation proceeds via distinct transcriptomic and phenotypic transitions[J]. JCI Insight, 2021, 6: e144799. doi: 10.1172/jci.insight.144799.
[20]	Fang L, Chen WC, Jaksch P, et al. Treprostinil reconstitutes mitochondrial organisation and structure in idiopathic pulmonary fibrosis cells[J]. Int J Mol Sci, 2023, 24: 12148. doi: 10.3390/ijms241512148.
[21]	New ML, White CM, McGonigle P, et al. Prostacyclin and EMT pathway markers for monitoring response to lung cancer chemoprevention[J]. Cancer Prev Res(Phila), 2018, 11: 643-654.
[22]	Chen HC, Chiou HC, Tsai ML, et al. Effects of montelukast on arsenic-induced epithelial-mesenchymal transi-tion and the role of reactive oxygen species production in human bronchial epithelial cells[J]. Front Pharmacol, 2022, 13: 877125. doi: 10.3389/fphar.2022.877125.
[23]	Nathan SD, Waxman A, Rajagopal S, et al. Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hyperten-sion: a post-hoc analysis of the INCREASE study[J]. Lancet Respir Med, 2021, 9: 1266-1274.
[24]	Waxman A, Restrepo-Jaramillo R, Thenappan T, et al. Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study[J]. Eur Respir J, 2023, 61: 2202414. doi: 10.1183/13993003.02414-2022.